Please check your internet connection and try again.
# Mylot%25252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252520at
## Overview
Mylot%25252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252520at is a combination product containing **Lidocaine** and **Prilocaine**. It is a topical anesthetic.
## Primary Indications
* **Topical anesthesia:** For minor surgical procedures such as needle insertion and venous cannulation.
* **Topical anesthesia:** For superficial dermatological procedures.
## Adult Dosing
* **Needle insertion/venous cannulation:** Apply approximately 1 gram of cream to an area of 20-25 cm² for 5 minutes.
* **Superficial dermatological procedures:** Apply 1-2 grams of cream to an area of 10 cm² for 5-15 minutes. A thicker layer and longer occlusion (up to 1 hour) may be used for longer procedures. Maximum total dose not specified, but large surface area application should be avoided.
## Pediatric Dosing
Dosing is weight-based and depends on age and surface area to be treated. Exact dosing should follow specific pediatric protocols. Generally:
* **Infants < 3 months:** Not recommended due to increased risk of methemoglobinemia.
* **Infants 3-12 months:** Maximum application area 10 cm², maximum dose 1 gram. Occlusion time 1 hour.
* **Children 1-5 years:** Maximum application area 20 cm², maximum dose 2 grams. Occlusion time 1 hour.
* **Children 6-12 years:** Maximum application area 40 cm², maximum dose 4 grams. Occlusion time 1 hour.
## Dose Adjustments
* **Renal Impairment:** Use with caution; no specific dose adjustment provided.
* **Hepatic Impairment:** Use with caution; no specific dose adjustment provided.
## Contraindications
* Hypersensitivity to lidocaine, prilocaine, or any component of the formulation.
* History of methemoglobinemia.
* Application to mucous membranes or broken/irritated skin.
* Premature infants or infants < 3 months of age (due to risk of methemoglobinemia).
## Adverse Effects
* **Common:** Local skin reactions (erythema, pallor, edema).
* **Rare but serious:** Allergic reactions, methemoglobinemia (especially in infants), systemic toxicity (CNS excitation or depression, cardiovascular effects) with excessive absorption.
## Key Drug Interactions
* **Methemoglobinemia-inducing agents:** Increased risk of methemoglobinemia when used with drugs like sulfonamides, dapsone, nitrofurantoin, and primaquine.
* **CYP1A2 and CYP3A4 inhibitors/inducers:** Lidocaine is metabolized by these enzymes; potential for altered clearance, though clinical significance with topical application is generally low.
## Monitoring
* Monitor for signs and symptoms of systemic toxicity (e.g., dizziness, confusion, seizures, bradycardia).
* Monitor for signs of methemoglobinemia (e.g., cyanosis, headache, fatigue).
## Clinical Pearls
* Adequate occlusion is crucial for effective anesthesia.
* Avoid application to large surface areas, especially in children and patients with compromised skin integrity, to minimize systemic absorption.
* Wash hands thoroughly after application.
* Onset of action is typically within 5 minutes, with peak effect around 10-15 minutes.
**Disclaimer:** This information is intended for clinical use and does not replace full prescribing information. Always consult the most current product labeling and local protocols for definitive guidance.
